<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870411</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210167</org_study_id>
    <secondary_id>2021-A00181-40</secondary_id>
    <nct_id>NCT04870411</nct_id>
  </id_info>
  <brief_title>Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics</brief_title>
  <acronym>COVADIS</acronym>
  <official_title>Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunov</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination against the new coronavirus (SARS-CoV-2) was extended to patients at risk of&#xD;
      severe forms of Covid-19, including in particular patients with autoimmune and inflammatory&#xD;
      diseases treated by immunosuppressants and/or biologics.&#xD;
&#xD;
      In this particular population, the effectiveness of vaccines, in particular influenza and&#xD;
      pneumococcal vaccinations, is often reduced, especially in case of treatment with rituximab&#xD;
      and / or methotrexate.&#xD;
&#xD;
      Regarding the SARS-CoV-2 vaccine, the studies that allowed the marketing authorization of the&#xD;
      available vaccines did not include patients treated with immunosuppressants or&#xD;
      immunomodulators.&#xD;
&#xD;
      Thus, the impact of treatments on the production of neutralizing antibodies and specific T&#xD;
      lymphocytes is not known.&#xD;
&#xD;
      The goal of this study is to assess the immune response to the SARS-CoV-2 vaccine in patients&#xD;
      with autoimmune and inflammatory diseases treated with immunosuppressants or&#xD;
      immunomodulators.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">November 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with neutralizing antibody</measure>
    <time_frame>1 month after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti-SARS-CoV2 specific T lymphocytes</measure>
    <time_frame>1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti-SARS-CoV2 specific T lymphocytes</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti-SARS-CoV2 specific T lymphocytes</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti-SARS-CoV2 specific T lymphocytes</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic infection by Covid 19 during follow-up</measure>
    <time_frame>1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic infection by Covid 19 during follow-up</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic infection by Covid 19 during follow-up</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic infection by Covid 19 during follow-up</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody and anti-SARS-CoV2 specific T cells according to the immunosuppressive or immunomodulative treatment</measure>
    <time_frame>1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody and anti-SARS-CoV2 specific T cells according to the immunosuppressive or immunomodulative treatment</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody and anti-SARS-CoV2 specific T cells according to the immunosuppressive or immunomodulative treatment</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with neutralizing antibody and anti-SARS-CoV2 specific T cells according to the immunosuppressive or immunomodulative treatment</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with flair of autoimmune disease</measure>
    <time_frame>1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with flair of autoimmune disease</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with flair of autoimmune disease</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with flair of autoimmune disease</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment-related adverse events grade 3 or 4</measure>
    <time_frame>1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment-related adverse events grade 3 or 4</measure>
    <time_frame>3 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment-related adverse events grade 3 or 4</measure>
    <time_frame>6 months after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment-related adverse events grade 3 or 4</measure>
    <time_frame>12 months after vaccination</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Inflammatory Disorder</condition>
  <arm_group>
    <arm_group_label>Patients with auto-immune or autoinflammatory diseases</arm_group_label>
    <description>Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without auto-immune or autoinflammatory diseases</arm_group_label>
    <description>Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination</description>
    <arm_group_label>Patients with auto-immune or autoinflammatory diseases</arm_group_label>
    <arm_group_label>Patients without auto-immune or autoinflammatory diseases</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants&#xD;
        and/or biologics = 170 patients Patients without auto-immune or autoinflammatory diseases&#xD;
        and not treated with immunosuppressants and/or biologics = 30 patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1 :&#xD;
&#xD;
          -  Patient over 18 years old,&#xD;
&#xD;
          -  Patient informed and not opposed to participate&#xD;
&#xD;
          -  Patient followed for an autoimmune or inflammatory disease (vasculitis, systemic&#xD;
             lupus, systemic sclerosis, non-infectious uveitis)&#xD;
&#xD;
          -  Treatment with immunosuppressant and / or immunomodulator&#xD;
&#xD;
          -  Group 2 :&#xD;
&#xD;
          -  Patient over 18 years old,&#xD;
&#xD;
          -  Patient informed and not opposed to participate&#xD;
&#xD;
          -  Patient not followed for an autoimmune or inflammatory disease (vasculitis, systemic&#xD;
             lupus, systemic sclerosis, non-infectious uveitis)&#xD;
&#xD;
          -  Absence of treatment with immunosuppressant and / or immunomodulator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to vaccination&#xD;
&#xD;
          -  Progressive cancer&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Current infection less than 3 weeks old&#xD;
&#xD;
          -  Weight less than 40 kg&#xD;
&#xD;
          -  Patient under tutor- or curator-ship&#xD;
&#xD;
          -  Patient without health insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jérôme HADJADJ</last_name>
    <phone>00 33 1 58 41 41 18</phone>
    <email>jerome.hadjadj@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI-GODARD</last_name>
    <phone>00 33 1 58 41 11 90</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal medicine Service - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme HADJADJ</last_name>
      <phone>00 33 1 58 41 41 18</phone>
      <email>jerome.hadjadj@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.</citation>
    <PMID>32105632</PMID>
  </reference>
  <reference>
    <citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.</citation>
    <PMID>33378609</PMID>
  </reference>
  <reference>
    <citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.</citation>
    <PMID>33301246</PMID>
  </reference>
  <reference>
    <citation>Sacre K, Goulenok T, Bahuaud M, Francois C, Van der Haegen MC, Alexandra JF, Aucouturier P, Hurtado-Nedelec M, Moins-Teisserenc H, Batteux F, Papo T. Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2018 Oct;77(10):1540-1542. doi: 10.1136/annrheumdis-2017-212789. Epub 2018 Feb 14.</citation>
    <PMID>29444908</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>vaccine</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>autoimmune diseases</keyword>
  <keyword>immunosuppressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

